Scholarlink

Background <p>Management of pelvic fracture-related urethral injury (PFUI) in children remains debated due to various complications. Patients typically receive either primary realignment (PR) or suprapubic cystostomy with delayed urethroplasty (SCDU), but optimal outcomes are unclear. This study evaluates these two surgical techniques by reviewing 20 years of case data and existing literature.</p> Methods <p>We retrospectively analyzed patients treated for PFUI from 2004 to 2023, with a median follow-up of 2 years (1–15 years). Additionally, we performed a meta-analysis of relevant literature, searching PubMed, Web of Science, and Cochrane databases. Eight studies, including ours, were included in the analysis.</p> Results <p>Sixty-eight boys with PFUI (median age: 7.3 years; range: 4.8–10.8) underwent PR (39) or SCDU (29). Postoperative complications—urethral strictures, urinary incontinence, calculus, infections, and erectile dysfunction—occurred in PR vs. SCDU groups as follows: 38.5% vs. 51.7% (<i>p</i> = 0.276); 12.8% vs. 3.45% (<i>p</i> = 0.360); 7.7% vs. 13.8% (<i>p</i> = 0.678); 56.4% vs. 93.1% (<i>p</i> &lt; 0.001); and15.4% vs. 3.5% (<i>p</i> = 0.231), respectively. PR was associated with lower costs and higher quality of life. The meta-analysis of eight studies involving 432 patients showed no significant differences between PR and SCDU in urethral stricture rates (OR = 0.60, 95% CI 0.33–1.10, <i>p</i> = 0.10), urinary incontinence (OR = 0.94, 95% CI 0.52–1.70, <i>p</i> = 0.84), and erectile dysfunction (OR = 0.85, 95% CI 0.41–1.76, <i>p</i> = 0.65).</p> Conclusion <p>There was no difference in complications between the two surgical modalities at long-term follow-up, however, PR presents more advantages in reduce operative times, frequency of postoperative infections, cost, and long-term quality of life.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment and prognosis of pelvic-related urethral injuries in children: a 20-year single-center study and systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月4日

查看全文
  • Kongkong Cui,
  • Peng Hong,
  • Honggang Fang,
  • Jie Lin,
  • Zaihong Hu,
  • Xiaomao Tian,
  • Deying Zhang,
  • Shengde Wu,
  • Xing Liu,
  • Qinlin Shi,
  • Guanghui Wei

摘要

Background

Management of pelvic fracture-related urethral injury (PFUI) in children remains debated due to various complications. Patients typically receive either primary realignment (PR) or suprapubic cystostomy with delayed urethroplasty (SCDU), but optimal outcomes are unclear. This study evaluates these two surgical techniques by reviewing 20 years of case data and existing literature.

Methods

We retrospectively analyzed patients treated for PFUI from 2004 to 2023, with a median follow-up of 2 years (1–15 years). Additionally, we performed a meta-analysis of relevant literature, searching PubMed, Web of Science, and Cochrane databases. Eight studies, including ours, were included in the analysis.

Results

Sixty-eight boys with PFUI (median age: 7.3 years; range: 4.8–10.8) underwent PR (39) or SCDU (29). Postoperative complications—urethral strictures, urinary incontinence, calculus, infections, and erectile dysfunction—occurred in PR vs. SCDU groups as follows: 38.5% vs. 51.7% (p = 0.276); 12.8% vs. 3.45% (p = 0.360); 7.7% vs. 13.8% (p = 0.678); 56.4% vs. 93.1% (p < 0.001); and15.4% vs. 3.5% (p = 0.231), respectively. PR was associated with lower costs and higher quality of life. The meta-analysis of eight studies involving 432 patients showed no significant differences between PR and SCDU in urethral stricture rates (OR = 0.60, 95% CI 0.33–1.10, p = 0.10), urinary incontinence (OR = 0.94, 95% CI 0.52–1.70, p = 0.84), and erectile dysfunction (OR = 0.85, 95% CI 0.41–1.76, p = 0.65).

Conclusion

There was no difference in complications between the two surgical modalities at long-term follow-up, however, PR presents more advantages in reduce operative times, frequency of postoperative infections, cost, and long-term quality of life.

Clinical trial number

Not applicable.